Cite
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
MLA
Yau, Thomas, et al. “Nivolumab versus Sorafenib in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomised, Multicentre, Open-Label, Phase 3 Trial.” Lancet Oncology, vol. 23, no. 1, Jan. 2022, pp. 77–90. EBSCOhost, https://doi.org/10.1016/S1470-2045(21)00604-5.
APA
Yau, T., Park, J.-W., Finn, R. S., Cheng, A.-L., Mathurin, P., Edeline, J., Kudo, M., Harding, J. J., Merle, P., Rosmorduc, O., Wyrwicz, L., Schott, E., Choo, S. P., Kelley, R. K., Sieghart, W., Assenat, E., Zaucha, R., Furuse, J., Abou-Alfa, G. K., & El-Khoueiry, A. B. (2022). Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology, 23(1), 77–90. https://doi.org/10.1016/S1470-2045(21)00604-5
Chicago
Yau, Thomas, Joong-Won Park, Richard S Finn, Ann-Lii Cheng, Philippe Mathurin, Julien Edeline, Masatoshi Kudo, et al. 2022. “Nivolumab versus Sorafenib in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomised, Multicentre, Open-Label, Phase 3 Trial.” Lancet Oncology 23 (1): 77–90. doi:10.1016/S1470-2045(21)00604-5.